Paper abstract: CRISPR-Cas9 gene-editing technology has revolutionised the creation of precise and permanent modifications to DNA, enabling the generation of diverse animal models for investigating potential treatments. Here, we provide a protocol for the use of CRISPR-Cas9 to create murine models of Duchenne Muscular Dystrophy (DMD) along with a step-by-step guide for their phenotypic and molecular characterisation. The experimental procedures include CRISPR microinjection of embryos, molecular testing at the DNA, RNA, and protein levels, forelimb grip strength testing, immunostaining and serum creatine kinase (CK) testing. We further provide suggestions for analysis and interpretation of the generated data, as well as the limitations of our approach. These protocols are designed for researchers who intend on generating and using mouse models to study DMD as well as those seeking a detailed framework of phenotyping to contribute to the broader landscape of genetic disorder investigations.
Protocol summary: Here we demonstrate the sampling of blood from the lateral tail vein of mice. Tail vein bleeding is necessary to isolate serum for downstream assessment of serum creatine kinase (CK) levels in our mouse model of Duchenne Muscular Dystrophy (DMD). We anticipate elevated serum CK levels in the DMD model compared to its wildtype counterparts, serving as a key indicator of the pathological changes associated with DMD.